Adiponectin

Last updated
ADIPOQ
PBB Protein ADIPOQ image.jpg
Available structures
PDB Ortholog search: PDBe RCSB
Identifiers
Aliases ADIPOQ , ACDC, ACRP30, ADIPQTL1, ADPN, APM-1, APM1, GBP28, adiponectin, C1Q and collagen domain containing, Adiponectin
External IDs OMIM: 605441 MGI: 106675 HomoloGene: 3525 GeneCards: ADIPOQ
Orthologs
SpeciesHumanMouse
Entrez
Ensembl
UniProt
RefSeq (mRNA)

NM_001177800
NM_004797

NM_009605

RefSeq (protein)

NP_001171271
NP_004788

NP_033735

Location (UCSC) Chr 3: 186.84 – 186.86 Mb Chr 16: 22.97 – 22.98 Mb
PubMed search [3] [4]
Wikidata
View/Edit Human View/Edit Mouse

Adiponectin (also referred to as GBP-28, apM1, AdipoQ and Acrp30) is a protein hormone and adipokine, which is involved in regulating glucose levels and fatty acid breakdown. [5] [6] In humans, it is encoded by the ADIPOQ gene and is produced primarily in adipose tissue, but also in muscle and even in the brain. [7] [8]

Contents

Structure

Adiponectin is a 244-amino-acid-long polypeptide (protein). It has four distinct regions: The first is a short signal sequence that targets the hormone for secretion outside the cell; next is a short region that varies between species; the third is a 65-amino acid region with similarity to collagenous proteins; the last is a globular domain. Overall, this protein shows similarity to the complement 1Q factors (C1Q), but when the three-dimensional structure of the globular region was determined, a striking similarity to TNFα was observed, despite unrelated protein sequences. [9]

Function

Adiponectin is a protein hormone that modulates a number of metabolic processes, including glucose regulation and fatty acid oxidation. [10] [11] [12] Adiponectin is secreted from adipose tissue (and also from the placenta in pregnancy [13] ) into the bloodstream and is very abundant in plasma relative to many hormones. High adiponectin levels correlate with a lower risk of diabetes mellitus type 2. [14] Plasma levels of adiponectin are lower in obese subjects than in lean subjects. [15] Many studies have found adiponectin to be inversely correlated with body mass index in patient populations. [16] However, a meta analysis was not able to confirm this association in healthy adults. [17] Circulating adiponectin concentrations increase during caloric restriction in animals and humans, such as in patients with anorexia nervosa. Furthermore, a recent study suggests that adipose tissue within bone marrow, which increases during caloric restriction, contributes to elevated circulating adiponectin in this context. [18]

Transgenic mice with increased adiponectin show reduced adipocyte differentiation and increased energy expenditure associated with mitochondrial uncoupling. [19] The hormone plays a role in the suppression of the metabolic derangements that may result in type 2 diabetes, [16] obesity, atherosclerosis, [12] non-alcoholic fatty liver disease (NAFLD) and an independent risk factor for metabolic syndrome. [20] Adiponectin in combination with leptin has been shown to completely reverse insulin resistance in mice. [21] Adiponectin enhances insulin sensitivity primarily though regulation of fatty acid oxidation and suppression of hepatic glucose production . [22]

Adiponectin is secreted into the bloodstream, where it accounts for about 0.01% of all plasma protein at around 5-10 μg/mL. In adults, plasma concentrations are higher in females than males, and are reduced in diabetics compared to nondiabetics. Weight reduction significantly increases circulating concentrations. [23]

Adiponectin automatically self-associates into larger structures. Initially, three adiponectin molecules bind together to form a homotrimer. The trimers continue to self-associate and form hexamers or dodecamers. Like the plasma concentration, the relative levels of the higher-order structures are sexually dimorphic, where females have increased proportions of the high-molecular-weight forms. Recent studies showed that the high-molecular-weight form may be the most biologically active form regarding glucose homeostasis. [15] High-molecular-weight adiponectin was further found to be associated with a lower risk of diabetes with similar magnitude of association as total adiponectin. [24] However, coronary artery disease has been found to be positively associated with high molecular weight adiponectin, but not with low molecular weight adiponectin. [25]

Adiponectin exerts some of its weight-reduction effects via the brain. This is similar to the action of leptin; [26] adiponectin and leptin can act synergistically.

Adiponectin promoted synaptic and memory function in the brain. [27] Humans with lower levels of adiponectin have reduced cognitive function. [27]

Receptors

Adiponectin binds to a number of receptors. So far, two receptors have been identified with homology to G protein-coupled receptors, and one receptor similar to the cadherin family: [28] [29]

These have distinct tissue specificities within the body and have different affinities to the various forms of adiponectin. AdipoR1 is enriched in skeletal muscle, whereas AdipoR2 is enriched in liver. [8] Six months of exercise has been shown in rats to double muscle AdipoR1. [8]

The receptors affect the downstream target AMP kinase, an important cellular metabolic rate control point. Expression of the receptors is correlated with insulin levels, as well as reduced in mouse models of diabetes, particularly in skeletal muscle and adipose tissue. [30] [31]

In 2016, the University of Tokyo announced that it would launch an investigation into claims of fabrication of AdipoR1 and AdipoR2 identification data, as accused by an anonymous person/group called Ordinary_researchers. [32]

Discovery

Adiponectin was first characterised in 1995 in differentiating 3T3-L1 adipocytes (Scherer PE et al.). [33] In 1996 it was characterised in mice as the mRNA transcript most highly expressed in adipocytes. [7] In 2007, adiponectin was identified as a transcript highly expressed in preadipocytes [34] (precursors of fat cells) differentiating into adipocytes. [34] [35]

The human homologue was identified as the most abundant transcript in adipose tissue. Contrary to expectations, despite being produced in adipose tissue, adiponectin was found to be decreased in obesity. [12] [16] [26] [11] This downregulation has not been fully explained. The gene was localised to chromosome 3q27, a region highlighted as affecting genetic susceptibility to type 2 diabetes and obesity. Supplementation by differing forms of adiponectin was able to improve insulin control, blood glucose and triglyceride levels in mouse models.

The gene was investigated for variants that predispose to type 2 diabetes. [26] [34] [36] [37] [38] [39] Several single nucleotide polymorphisms in the coding region and surrounding sequence were identified from several different populations, with varying prevalences, degrees of association and strength of effect on type 2 diabetes. Berberine, an isoquinoline alkaloid, has been shown to increase adiponectin expression, [40] which partly explains its beneficial effects on metabolic disturbances. Mice fed the omega-3 fatty acids eicosapentaenoic acid  (EPA) and docosahexaenoic acid  (DHA) have shown increased plasma adiponectin. [41] Curcumin, capsaicin, gingerol, and catechins have also been found to increase adiponectin expression. [42]

Phylogenetic distribution includes expression in birds [43] and fish. [44]

Metabolic

Adiponectin effects:

Regulation of adiponectin

Hypoadiponectinemia

A low level of adiponectin is an independent risk factor for developing:

Other

Lower levels of adiponectin are associated with ADHD in adults. [48]

Adiponectin levels were found to be increased in rheumatoid arthritis patients responding to DMARDs or TNF inhibitor therapy. [49]

A low adiponectin to leptin ratio has been found in patients with COVID-19 pneumonia compared to healthy controls. [50]

Exercise induced release of adiponectin increased hippocampal growth and led to antidepressive symptoms in mice. [51]

Several studies have found a positive correlation in caffeine consumption and increased adiponectin levels, although the mechanism for this is unknown and requires more research. [52]

As a medication target

Circulating levels of adiponectin can indirectly be increased through lifestyle modifications and certain medications such as statins. [53]

A small molecule adiponectin receptor AdipoR1 and AdipoR2 agonist, AdipoRon, has been reported. [54] In 2016, the University of Tokyo announced it was launching an investigation into anonymously made claims of fabricated and falsified data on AdipoR1, AdipoR2, and AdipoRon. [32]

Extracts of sweet potatoes have been reported to increase levels of adiponectin and thereby improve glycemic control in humans. [55] However, a systematic review concluded there is insufficient evidence to support the consumption of sweet potatoes to treat type 2 diabetes mellitus. [56]

Adiponectin is apparently able to cross the blood-brain-barrier. [51] However, conflicting data on this issue exist. [57] Adiponectin has a half-life of 2.5 hours in humans. [58]

Related Research Articles

<span class="mw-page-title-main">Leptin</span> Hormone that inhibits hunger

Leptin is a protein hormone predominantly made by adipocytes. Its primary role is likely to regulate long-term energy balance.

<span class="mw-page-title-main">Lipolysis</span> Metabolism involving breakdown of lipids

Lipolysis is the metabolic pathway through which lipid triglycerides are hydrolyzed into a glycerol and free fatty acids. It is used to mobilize stored energy during fasting or exercise, and usually occurs in fat adipocytes. The most important regulatory hormone in lipolysis is insulin; lipolysis can only occur when insulin action falls to low levels, as occurs during fasting. Other hormones that affect lipolysis include leptin, glucagon, epinephrine, norepinephrine, growth hormone, atrial natriuretic peptide, brain natriuretic peptide, and cortisol.

<span class="mw-page-title-main">Brown adipose tissue</span> Type of adipose tissue

Brown adipose tissue (BAT) or brown fat makes up the adipose organ together with white adipose tissue. Brown adipose tissue is found in almost all mammals.

<span class="mw-page-title-main">Adipose tissue</span> Loose connective tissue composed mostly by adipocytes

Adipose tissue is a loose connective tissue composed mostly of adipocytes. It also contains the stromal vascular fraction (SVF) of cells including preadipocytes, fibroblasts, vascular endothelial cells and a variety of immune cells such as adipose tissue macrophages. Its main role is to store energy in the form of lipids, although it also cushions and insulates the body.

<span class="mw-page-title-main">Adipocyte</span> Cells that primarily compose adipose tissue, specialized in storing energy as fat

Adipocytes, also known as lipocytes and fat cells, are the cells that primarily compose adipose tissue, specialized in storing energy as fat. Adipocytes are derived from mesenchymal stem cells which give rise to adipocytes through adipogenesis. In cell culture, adipocyte progenitors can also form osteoblasts, myocytes and other cell types.

<span class="mw-page-title-main">Resistin</span> Mammalian protein found in Homo sapiens

Resistin also known as adipose tissue-specific secretory factor (ADSF) or C/EBP-epsilon-regulated myeloid-specific secreted cysteine-rich protein (XCP1) is a cysteine-rich peptide hormone derived from adipose tissue that in humans is encoded by the RETN gene.

<span class="mw-page-title-main">Ghrelin</span> Peptide hormone involved in appetite regulation

Ghrelin is a hormone primarily produced by enteroendocrine cells of the gastrointestinal tract, especially the stomach, and is often called a "hunger hormone" because it increases the drive to eat. Blood levels of ghrelin are highest before meals when hungry, returning to lower levels after mealtimes. Ghrelin may help prepare for food intake by increasing gastric motility and stimulating the secretion of gastric acid.

The adipokines, or adipocytokines are cytokines secreted by adipose tissue. Some contribute to an obesity-related low-grade state of inflammation or to the development of metabolic syndrome, a constellation of diseases including, but not limited to, type 2 diabetes, cardiovascular disease and atherosclerosis. The first adipokine to be discovered was leptin in 1994. Since that time, hundreds of adipokines have been discovered.

<span class="mw-page-title-main">Perilipin-1</span> Protein in humans

Perilipin, also known as lipid droplet-associated protein, perilipin 1, or PLIN, is a protein that, in humans, is encoded by the PLIN gene. The perilipins are a family of proteins that associate with the surface of lipid droplets. Phosphorylation of perilipin is essential for the mobilization of fats in adipose tissue.

<span class="mw-page-title-main">White adipose tissue</span> Fatty tissue composed of white adipocytes

White adipose tissue or white fat is one of the two types of adipose tissue found in mammals. The other kind is brown adipose tissue. White adipose tissue is composed of monolocular adipocytes.

<span class="mw-page-title-main">Fatty acid-binding protein</span>

The fatty-acid-binding proteins (FABPs) are a family of transport proteins for fatty acids and other lipophilic substances such as eicosanoids and retinoids. These proteins are thought to facilitate the transfer of fatty acids between extra- and intracellular membranes. Some family members are also believed to transport lipophilic molecules from outer cell membrane to certain intracellular receptors such as PPAR. The FABPs are intracellular carriers that “solubilize” the endocannabinoid anandamide (AEA), transporting AEA to the breakdown by FAAH, and compounds that bind to FABPs block AEA breakdown, raising its level. The cannabinoids are also discovered to bind human FABPs that function as intracellular carriers, as THC and CBD inhibit the cellular uptake and catabolism of AEA by targeting FABPs. Competition for FABPs may in part or wholly explain the increased circulating levels of endocannabinoids reported after consumption of cannabinoids. Levels of fatty-acid-binding protein have been shown to decline with ageing in the mouse brain, possibly contributing to age-associated decline in synaptic activity.

<span class="mw-page-title-main">Obesogen</span> Foreign chemical compound that disrupts lipid balance causing obseity

Obesogens are certain chemical compounds that are hypothesised to disrupt normal development and balance of lipid metabolism, which in some cases, can lead to obesity. Obesogens may be functionally defined as chemicals that inappropriately alter lipid homeostasis and fat storage, change metabolic setpoints, disrupt energy balance or modify the regulation of appetite and satiety to promote fat accumulation and obesity.

<span class="mw-page-title-main">Adiponectin receptor 1</span> Protein-coding gene in the species Homo sapiens

Adiponectin receptor 1 (AdipoR1) is a protein which in humans is encoded by the ADIPOR1 gene. It is a member of the progestin and adipoQ receptor (PAQR) family, and is also known as PAQR1.

<span class="mw-page-title-main">Adipose triglyceride lipase</span> Mammalian protein found in Homo sapiens

Adipose triglyceride lipase, also known as patatin-like phospholipase domain-containing protein 2 and ATGL, is an enzyme that in humans is encoded by the PNPLA2 gene. ATGL catalyses the first reaction of lipolysis, where triacylglycerols are hydrolysed to diacylglycerols.

Adipose tissue is an endocrine organ that secretes numerous protein hormones, including leptin, adiponectin, and resistin. These hormones generally influence energy metabolism, which is of great interest to the understanding and treatment of type 2 diabetes and obesity.

<span class="mw-page-title-main">Chemerin</span> Protein-coding gene in the species Homo sapiens

Chemerin, also known as retinoic acid receptor responder protein 2 (RARRES2), tazarotene-induced gene 2 protein (TIG2), or RAR-responsive protein TIG2 is a protein that in humans is encoded by the RARRES2 gene.

<span class="mw-page-title-main">Adipogenesis</span>

Adipogenesis is the formation of adipocytes from stem cells. It involves 2 phases, determination, and terminal differentiation. Determination is mesenchymal stem cells committing to the adipocyte precursor cells, also known as lipoblasts or preadipocytes which lose the potential to differentiate to other types of cells such as chondrocytes, myocytes, and osteoblasts. Terminal differentiation is that preadipocytes differentiate into mature adipocytes. Adipocytes can arise either from preadipocytes resident in adipose tissue, or from bone-marrow derived progenitor cells that migrate to adipose tissue.

<span class="mw-page-title-main">Lipotoxicity</span> Metabolic syndrome

Lipotoxicity is a metabolic syndrome that results from the accumulation of lipid intermediates in non-adipose tissue, leading to cellular dysfunction and death. The tissues normally affected include the kidneys, liver, heart and skeletal muscle. Lipotoxicity is believed to have a role in heart failure, obesity, and diabetes, and is estimated to affect approximately 25% of the adult American population.

<span class="mw-page-title-main">AdipoRon</span> Chemical compound

AdipoRon is a selective, orally active, synthetic small-molecule agonist of the adiponectin receptor 1 (AdipoR1) and adiponectin receptor 2 (AdipoR2). It activates AMPK and PPARα signaling and ameliorates insulin resistance, dyslipidemia, and glucose intolerance in db/db mice. Moreover, AdipoRon has been found to extend the lifespans of db/db mice fed a high-fat diet, as well as improve exercise endurance. The compound was discovered by Japanese researchers in 2013 via screening of a compound library, and is the first orally active, small-molecule agonist of the adiponectin receptors to be identified.

Asprosin is a protein hormone produced by mammals in tissues that stimulates the liver to release glucose into the blood stream. Asprosin is encoded by the gene FBN1 as part of the protein profibrillin and is released from the C-terminus of the latter by specific proteolysis. In the liver, asprosin activates rapid glucose release via a cyclic adenosine monophosphate (cAMP)-dependent pathway.

References

  1. 1 2 3 GRCh38: Ensembl release 89: ENSG00000181092 - Ensembl, May 2017
  2. 1 2 3 GRCm38: Ensembl release 89: ENSMUSG00000022878 - Ensembl, May 2017
  3. "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. Ellulu MS, Patimah I, Khaza'ai H, Rahmat A, Abed Y (2017-06-08). "Obesity and inflammation the linking mechanism and the complications". Archives of Medical Science. 13 (4): 851–863. doi:10.5114/aoms.2016.58928. ISSN   1734-1922. PMC   5507106 . PMID   28721154.
  6. Amerikanou C, Kaliora AC, Gioxari A (2021-12-01). "The efficacy of Panax ginseng in obesity and the related metabolic disorders". Pharmacological Research - Modern Chinese Medicine. 1: 100013. doi:10.1016/j.prmcm.2021.100013. ISSN   2667-1425.
  7. 1 2 Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Matsubara K (April 1996). "cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1)". Biochemical and Biophysical Research Communications. 221 (2): 286–289. doi:10.1006/bbrc.1996.0587. PMID   8619847.
  8. 1 2 3 Martinez-Huenchullan SF, Tam CS, Ban LA, Ehrenfeld-Slater P, Mclennan SV, Twigg SM (January 2020). "Skeletal muscle adiponectin induction in obesity and exercise". Metabolism. 102: 154008. doi: 10.1016/j.metabol.2019.154008 . PMID   31706980.
  9. Shapiro L, Scherer PE (March 1998). "The crystal structure of a complement-1q family protein suggests an evolutionary link to tumor necrosis factor". Current Biology. 8 (6): 335–338. Bibcode:1998CBio....8..335S. doi: 10.1016/S0960-9822(98)70133-2 . PMID   9512423. S2CID   14287212.
  10. 1 2 3 Ghoshal K, et al. (June 2021). "Adiponectin Genetic Variant and Expression Coupled with Lipid Peroxidation Reveal New Signatures in Diabetic Dyslipidemia". Biochemical Genetics. 59 (3): 781–798. doi:10.1007/s10528-021-10030-5. PMID   33543406. S2CID   231817353.
  11. 1 2 3 4 Ghoshal K, Bhattacharyya M (February 2015). "Adiponectin: Probe of the molecular paradigm associating diabetes and obesity". World J Diabetes. 15 (6(1)): 151–166. doi: 10.4239/wjd.v6.i1.151 . PMC   4317307 . PMID   25685286.
  12. 1 2 3 4 Díez JJ, Iglesias P (March 2003). "The role of the novel adipocyte-derived hormone adiponectin in human disease". European Journal of Endocrinology. 148 (3): 293–300. doi: 10.1530/eje.0.1480293 . PMID   12611609.
  13. Chen J, Tan B, Karteris E, Zervou S, Digby J, Hillhouse EW, et al. (June 2006). "Secretion of adiponectin by human placenta: differential modulation of adiponectin and its receptors by cytokines". Diabetologia. 49 (6): 1292–1302. doi: 10.1007/s00125-006-0194-7 . PMID   16570162.
  14. Li S, Shin HJ, Ding EL, van Dam RM (July 2009). "Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis". JAMA. 302 (2): 179–188. doi: 10.1001/jama.2009.976 . PMID   19584347.
  15. 1 2 Oh DK, Ciaraldi T, Henry RR (May 2007). "Adiponectin in health and disease". Diabetes, Obesity & Metabolism. 9 (3): 282–289. doi:10.1111/j.1463-1326.2006.00610.x. PMID   17391153. S2CID   23270116.
  16. 1 2 3 Ukkola O, Santaniemi M (November 2002). "Adiponectin: a link between excess adiposity and associated comorbidities?". Journal of Molecular Medicine. 80 (11): 696–702. doi:10.1007/s00109-002-0378-7. PMID   12436346. S2CID   23209903.
  17. Kuo SM, Halpern MM (December 2011). "Lack of association between body mass index and plasma adiponectin levels in healthy adults". International Journal of Obesity. 35 (12): 1487–1494. doi: 10.1038/ijo.2011.20 . PMID   21364526.
  18. Cawthorn WP, Scheller EL, Learman BS, Parlee SD, Simon BR, Mori H, et al. (August 2014). "Bone marrow adipose tissue is an endocrine organ that contributes to increased circulating adiponectin during caloric restriction". Cell Metabolism. 20 (2): 368–375. doi:10.1016/j.cmet.2014.06.003. PMC   4126847 . PMID   24998914.
  19. 1 2 Bauche IB, El Mkadem SA, Pottier AM, Senou M, Many MC, Rezsohazy R, et al. (April 2007). "Overexpression of adiponectin targeted to adipose tissue in transgenic mice: impaired adipocyte differentiation". Endocrinology. 148 (4): 1539–1549. doi: 10.1210/en.2006-0838 . PMID   17204560.
  20. 1 2 Renaldi O, Pramono B, Sinorita H, Purnomo LB, Asdie RH, Asdie AH (January 2009). "Hypoadiponectinemia: a risk factor for metabolic syndrome". Acta Medica Indonesiana. 41 (1): 20–24. PMID   19258676.
  21. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, et al. (August 2001). "The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity". Nature Medicine. 7 (8): 941–946. doi:10.1038/90984. PMID   11479627. S2CID   31308235.
  22. Fisman EZ, Tenenbaum A (June 2014). "Adiponectin: a manifold therapeutic target for metabolic syndrome, diabetes, and coronary disease?". Cardiovascular Diabetology. 13 (1): 103. doi: 10.1186/1475-2840-13-103 . PMC   4230016 . PMID   24957699.
  23. Coppola A, Marfella R, Coppola L, Tagliamonte E, Fontana D, Liguori E, et al. (May 2009). "Effect of weight loss on coronary circulation and adiponectin levels in obese women". International Journal of Cardiology. 134 (3): 414–416. doi:10.1016/j.ijcard.2007.12.087. PMID   18378021.
  24. Zhu N, Pankow JS, Ballantyne CM, Couper D, Hoogeveen RC, Pereira M, et al. (November 2010). "High-molecular-weight adiponectin and the risk of type 2 diabetes in the ARIC study". The Journal of Clinical Endocrinology and Metabolism. 95 (11): 5097–5104. doi:10.1210/jc.2010-0716. PMC   2968724 . PMID   20719834.
  25. Rizza S, Gigli F, Galli A, Micchelini B, Lauro D, Lauro R, Federici M (April 2010). "Adiponectin isoforms in elderly patients with or without coronary artery disease". Journal of the American Geriatrics Society. 58 (4): 702–706. doi: 10.1111/j.1532-5415.2010.02773.x . PMID   20398150. S2CID   30291450.
  26. 1 2 3 4 5 6 7 Nedvídková J, Smitka K, Kopský V, Hainer V (2005). "Adiponectin, an adipocyte-derived protein" (PDF). Physiological Research. 54 (2): 133–140. doi:10.33549/physiolres.930600. PMID   15544426. S2CID   24141809.
  27. 1 2 Forny-Germano L, De Felice FG, Vieira MN (2019). "The Role of Leptin and Adiponectin in Obesity-Associated Cognitive Decline and Alzheimer's Disease". Frontiers in Neuroscience. 12: 1027. doi: 10.3389/fnins.2018.01027 . PMC   6340072 . PMID   30692905.
  28. Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S, et al. (June 2003). "Cloning of adiponectin receptors that mediate antidiabetic metabolic effects". Nature. 423 (6941): 762–769. Bibcode:2003Natur.423..762Y. doi:10.1038/nature01705. PMID   12802337. S2CID   52860797.
  29. Hug C, Wang J, Ahmad NS, Bogan JS, Tsao TS, Lodish HF (July 2004). "T-cadherin is a receptor for hexameric and high-molecular-weight forms of Acrp30/adiponectin". Proceedings of the National Academy of Sciences of the United States of America. 101 (28): 10308–10313. Bibcode:2004PNAS..10110308H. doi: 10.1073/pnas.0403382101 . PMC   478568 . PMID   15210937.
  30. Fang X, Sweeney G (November 2006). "Mechanisms regulating energy metabolism by adiponectin in obesity and diabetes". Biochemical Society Transactions. 34 (Pt 5): 798–801. doi:10.1042/BST0340798. PMID   17052201. S2CID   1473301.
  31. Bonnard C, Durand A, Vidal H, Rieusset J (February 2008). "Changes in adiponectin, its receptors and AMPK activity in tissues of diet-induced diabetic mice". Diabetes & Metabolism. 34 (1): 52–61. doi:10.1016/j.diabet.2007.09.006. PMID   18222103.
  32. 1 2 University of Tokyo to investigate data manipulation charges against six prominent research groups ScienceInsider, Dennis Normile, Sep 20, 2016
  33. Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF (November 1995). "A novel serum protein similar to C1q, produced exclusively in adipocytes". The Journal of Biological Chemistry. 270 (45): 26746–26749. doi: 10.1074/jbc.270.45.26746 . PMID   7592907.
  34. 1 2 3 4 Lara-Castro C, Fu Y, Chung BH, Garvey WT (June 2007). "Adiponectin and the metabolic syndrome: mechanisms mediating risk for metabolic and cardiovascular disease". Current Opinion in Lipidology. 18 (3): 263–270. doi:10.1097/MOL.0b013e32814a645f. PMID   17495599. S2CID   20799218.
  35. Matsuzawa Y, Funahashi T, Kihara S, Shimomura I (January 2004). "Adiponectin and metabolic syndrome". Arteriosclerosis, Thrombosis, and Vascular Biology. 24 (1): 29–33. doi: 10.1161/01.ATV.0000099786.99623.EF . PMID   14551151.
  36. 1 2 Hara K, Yamauchi T, Kadowaki T (April 2005). "Adiponectin: an adipokine linking adipocytes and type 2 diabetes in humans". Current Diabetes Reports. 5 (2): 136–140. doi:10.1007/s11892-005-0041-0. PMID   15794918. S2CID   23664493.
  37. 1 2 3 4 Vasseur F, Leprêtre F, Lacquemant C, Froguel P (April 2003). "The genetics of adiponectin". Current Diabetes Reports. 3 (2): 151–158. doi:10.1007/s11892-003-0039-4. PMID   12728641. S2CID   21611611.
  38. 1 2 Hug C, Lodish HF (April 2005). "The role of the adipocyte hormone adiponectin in cardiovascular disease". Current Opinion in Pharmacology. 5 (2): 129–134. doi:10.1016/j.coph.2005.01.001. PMID   15780820.
  39. 1 2 Vasseur F, Meyre D, Froguel P (November 2006). "Adiponectin, type 2 diabetes and the metabolic syndrome: lessons from human genetic studies". Expert Reviews in Molecular Medicine. 8 (27): 1–12. doi:10.1017/S1462399406000147. PMID   17112391. S2CID   20732833.
  40. Choi BH, Kim YH, Ahn IS, Ha JH, Byun JM, Do MS (2009). "The inhibition of inflammatory molecule expression on 3T3-L1 adipocytes by berberine is not mediated by leptin signaling". Nutrition Research and Practice. 3 (2): 84–88. doi:10.4162/nrp.2009.3.2.84. PMC   2788178 . PMID   20016706.
  41. Grimshaw CE, Matthews DA, Varughese KI, Skinner M, Xuong NH, Bray T, et al. (August 1992). "Characterization and nucleotide binding properties of a mutant dihydropteridine reductase containing an aspartate 37-isoleucine replacement". The Journal of Biological Chemistry. 267 (22): 15334–15339. doi: 10.1016/S0021-9258(19)49538-0 . PMID   1639779.
  42. Nigro E, Scudiero O, Monaco ML, Palmieri A, Mazzarella G, Costagliola C, et al. (2014). "New insight into adiponectin role in obesity and obesity-related diseases". BioMed Research International. 2014: 658913. doi: 10.1155/2014/658913 . PMC   4109424 . PMID   25110685.
  43. Yuan J, Liu W, Liu ZL, Li N (2006). "cDNA cloning, genomic structure, chromosomal mapping and expression analysis of ADIPOQ (adiponectin) in chicken". Cytogenetic and Genome Research. 112 (1–2): 148–151. doi:10.1159/000087527. PMID   16276104. S2CID   27327817.
  44. Nishio S, Gibert Y, Bernard L, Brunet F, Triqueneaux G, Laudet V (June 2008). "Adiponectin and adiponectin receptor genes are coexpressed during zebrafish embryogenesis and regulated by food deprivation". Developmental Dynamics. 237 (6): 1682–1690. doi: 10.1002/dvdy.21559 . hdl: 10536/DRO/DU:30062852 . PMID   18489000. S2CID   39211439.
  45. Hafiane A, Gasbarrino K, Daskalopoulou SS (November 2019). "The role of adiponectin in cholesterol efflux and HDL biogenesis and metabolism". Metabolism. 100: 153953. doi:10.1016/j.metabol.2019.153953. PMID   31377319. S2CID   203413137.
  46. Liu M, Liu F (October 2012). "Up- and down-regulation of adiponectin expression and multimerization: mechanisms and therapeutic implication". Biochimie. 94 (10): 2126–2130. doi:10.1016/j.biochi.2012.01.008. PMC   3542391 . PMID   22342903.
  47. Iwashima Y, Katsuya T, Ishikawa K, Ouchi N, Ohishi M, Sugimoto K, Fu Y, Motone M, Yamamoto K, Matsuo A, Ohashi K, Kihara S, Funahashi T, Rakugi H, Matsuzawa Y, Ogihara T (June 2004). "Hypoadiponectinemia Is an Independent Risk Factor for Hypertension". Hypertension. 43 (6): 1318–1323. doi: 10.1161/01.HYP.0000129281.03801.4b . ISSN   0194-911X. PMID   15123570. S2CID   9952849.
  48. Mavroconstanti T, Halmøy A, Haavik J (April 2014). "Decreased serum levels of adiponectin in adult attention deficit hyperactivity disorder". Psychiatry Research. 216 (1): 123–130. doi:10.1016/j.psychres.2014.01.025. PMID   24559850. S2CID   14858659.
  49. Kim KS, Choi HM, Ji HI, Song R, Yang HI, Lee SK, et al. (January 2014). "Serum adipokine levels in rheumatoid arthritis patients and their contributions to the resistance to treatment". Molecular Medicine Reports. 9 (1): 255–260. doi: 10.3892/mmr.2013.1764 . PMID   24173909.
  50. Tonon F, Bella SD, Giudici F, Zerbato V, Segat L, Koncan R, et al. (2022-04-26). Salvador J (ed.). "Discriminatory Value of Adiponectin to Leptin Ratio for COVID-19 Pneumonia". International Journal of Endocrinology. 2022: 1–9. doi: 10.1155/2022/9908450 . ISSN   1687-8345. PMC   9072020 . PMID   35529082.
  51. 1 2 Yau SY, Li A, Hoo RL, Ching YP, Christie BR, Lee TM, et al. (November 2014). "Physical exercise-induced hippocampal neurogenesis and antidepressant effects are mediated by the adipocyte hormone adiponectin". Proceedings of the National Academy of Sciences of the United States of America. 111 (44): 15810–15815. Bibcode:2014PNAS..11115810Y. doi: 10.1073/pnas.1415219111 . PMC   4226125 . PMID   25331877.
  52. Buscemi S, Marventano S, Antoci M, Cagnetti A, Castorina G, Galvano F, et al. (2016-08-01). "Coffee and metabolic impairment: An updated review of epidemiological studies". NFS Journal. 3: 1–7. doi: 10.1016/j.nfs.2016.02.001 . hdl: 10447/219127 . ISSN   2352-3646.
  53. Lim S, Quon MJ, Koh KK (April 2014). "Modulation of adiponectin as a potential therapeutic strategy". Atherosclerosis. 233 (2): 721–728. doi:10.1016/j.atherosclerosis.2014.01.051. PMID   24603219.
  54. Okada-Iwabu M, Yamauchi T, Iwabu M, Honma T, Hamagami K, Matsuda K, et al. (November 2013). "A small-molecule AdipoR agonist for type 2 diabetes and short life in obesity". Nature. 503 (7477): 493–499. Bibcode:2013Natur.503..493O. doi:10.1038/nature12656. PMID   24172895. S2CID   4447039.
  55. Ludvik B, Hanefeld M, Pacini G (July 2008). "Improved metabolic control by Ipomoea batatas (Caiapo) is associated with increased adiponectin and decreased fibrinogen levels in type 2 diabetic subjects". Diabetes, Obesity & Metabolism. 10 (7): 586–592. doi:10.1111/j.1463-1326.2007.00752.x. PMID   17645559. S2CID   30418587.
  56. Ooi CP, Loke SC (September 2013). "Sweet potato for type 2 diabetes mellitus". The Cochrane Database of Systematic Reviews. 9 (9): CD009128. doi:10.1002/14651858.CD009128.pub3. PMC   6486146 . PMID   24000051.
  57. Spranger J, Verma S, Göhring I, Bobbert T, Seifert J, Sindler AL, et al. (January 2006). "Adiponectin does not cross the blood-brain barrier but modifies cytokine expression of brain endothelial cells". Diabetes. 55 (1): 141–147. doi: 10.2337/diabetes.55.1.141 . PMID   16380487.
  58. Hoffstedt J, Arvidsson E, Sjölin E, Wåhlén K, Arner P (March 2004). "Adipose tissue adiponectin production and adiponectin serum concentration in human obesity and insulin resistance". The Journal of Clinical Endocrinology and Metabolism. 89 (3): 1391–1396. doi: 10.1210/jc.2003-031458 . PMID   15001639.